aTension.life develops precision medicine tools for hypertension, aiming to improve diagnosis and treatment strategies. They focus on tailoring interventions based on individual patient profiles to optimize outcomes for those with high blood pressure.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Hypertension often goes undetected, and secondary forms like primary aldosteronism frequently remain undiagnosed due to low screening rates. Traditional ELISA-based diagnostic tests suffer from variability and drug interference, leading clinicians to manage hypertension using a trial-and-error approach, often without identifying the underlying molecular causes. This results in delayed blood pressure control, patient frustration, inappropriate medication, and increased cardiovascular complications.
Solution
aTENSION.life offers the ALDO+ testing platform, a CE-IVD certified diagnostic tool that identifies common causes of uncontrolled hypertension, such as primary aldosteronism. The platform accurately analyzes key clinical hypertension parameters, including Angiotensin I, Angiotensin II, and Aldosterone, using mass spectrometry. This approach enables personalized and effective anti-hypertensive treatment strategies and serves as a screening tool for primary aldosteronism in routine diagnostics. aTENSION.life's Prep ‘n’ Ship™ model extends access to mass spectrometry-based diagnostics, allowing labs without mass spectrometry equipment to collect and prepare blood samples for analysis by specialized labs.
Target Audience
The primary audience includes clinicians, laboratories, and patients seeking precise and personalized diagnostic solutions for hypertension screening and profiling.
Features
- ALDO+ test directly measures Angiotensin I, Angiotensin II, and Aldosterone concentrations in serum using LC-MS/MS with internal standardization.
- Determination of Angiotensin II as the central blood pressure hormone and endogenous mediator of aldosterone release.
- Aldosterone-to-Angiotensin II ratio (AA2 ratio) demonstrates high PA screening performance with less drug interference compared to other methods (sensitivity 97% & specificity 81% at cut-off: 3.9 pmol/pmol).
- Provides information on the pharmacological efficacy of existing antihypertensive therapy with ACE inhibitors, angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs).
- Prep ‘n’ Ship™ model enables labs without mass spectrometry capabilities to offer ALDO+ testing.